MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$433,477K
Proceeds from exercise of
stock options
$29,587K
Proceeds from issuance of
common stock under the...
$354K
Net cash provided by
financing activities
$463,418K
Net increase
(decrease) in cash, cash...
$3,321K
Canceled cashflow
$460,097K
Maturities of marketable
securities
$118,693K
Stock-based compensation
$13,915K
Accrued expenses and
other liabilities
$3,186K
Amortization of premiums and
discounts on marketable...
-$511K
Noncash lease expense
$126K
Depreciation
$7K
Net cash used in
investing activities
-$441,566K
Net cash used in
operating activities
-$18,531K
Canceled cashflow
$118,693K
Canceled cashflow
$17,745K
Purchases of marketable
securities
$560,160K
Net loss
-$32,485K
Purchases of property and
equipment
$99K
Prepaid expenses, other
current and long-term...
$2,160K
Accounts payable
-$1,502K
Operating lease
liabilities
-$129K
Back
Back
Cash Flow
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)
source: myfinsight.com